

Sofosbuvir-Velpatasvir in Genotype 3 ASTRAL-3*

*Published in tandem with ASTRAL-2 Trial


Sofosbuvir-Velpatasvir in HCV Genotype 3

ASTRAL-3: Study Features

- **Design:** Randomized, placebo-controlled, open-label, phase 3 trial using a fixed-dose combination of sofosbuvir-velpatasvir for 12 weeks (compared with sofosbuvir + ribavirin) in treatment-naïve and treatment-experienced patients with GT 3 chronic HCV
- **Setting:** 76 sites in US, Canada, Europe, Australia, and New Zealand
- **Entry Criteria**
 - Chronic HCV GT 3
 - HCV RNA $\geq 10,000$ IU/mL at screening
 - Prior treatment failure with interferon allowed (but no prior NS5A or NS5B)
 - Patients with compensated cirrhosis allowed
- **Primary End Point:** SVR12

Sofosbuvir-Velpatasvir in HCV Genotype 3

ASTRAL-3: Study Design



*Randomization stratified by treatment experience and cirrhosis status.

Abbreviations: SOF-VEL = sofosbuvir-velpatasvir; RBV = ribavirin

Drug Dosing

Sofosbuvir-velpatasvir (400/100 mg): fixed-dose combination; one pill once daily


Sofosbuvir: 400 mg once daily

Ribavirin (weight-based and divided bid): 1000 mg/day if <75 kg or 1200 mg/day if ≥75 kg


Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Baseline Characteristics

Baseline Characteristics	Sofosbuvir-Velpatasvir (n = 277)	Sofosbuvir + Ribavirin (n = 275)
Age, mean (range)	49 (21-76)	50 (19-74)
Male, n (%)	170 (61)	174 (63)
Race, n (%)		
White	250 (90)	239 (87)
Black	3 (1)	1 (<1)
Asian	23 (8)	29 (11)
Body mass index, mean (range)	26 (17-48)	27 (17-56)
HCV RNA ≥800,000 IU/mL, n (%)	191 (69)	194 (71)
IL28B non-CC, n (%)	172 (62)	164 (60)
Cirrhosis, n (%)	80 (29)	83 (30)
Treatment-experienced, n (%)	71 (26)	71 (26)
Prior response, no./total (%)		
Non-response	20/71 (28)	24/71 (34)
Relapse or breakthrough	51/71 (72)	47/71 (66)

Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Results




Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Results



Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Results


SVR12 Results by Treatment Experience and Cirrhosis Status




Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Resistance

Baseline Resistance-Associated Variants (RAVs)

■ No NS5A RAVs ■ NS5A RAVs



Response to Treatment (SVR12)



* SVR12 in 84% (21/25) of patients with Y93H

Sofosbuvir-Velpatasvir in HCV Genotype 3

ASTRAL-3: Adverse Events

Adverse Event (AE), n (%)	Sofosbuvir-Velpatasvir (n = 277)	Sofosbuvir + Ribavirin (n = 275)
Discontinuation due to AE	0	9 (3)
Serious AEs	6 (2)	15 (5)
Deaths	0	3 (1)
Any AE in ≥10% of patients		
Fatigue	71 (26)	105 (38)
Headache	90 (32)	89 (32)
Nausea	46 (17)	58 (21)
Insomnia	31 (11)	74 (27)
Laboratory AEs		
Hemoglobin <10 g/dL	0	10 (4)
Total bilirubin >2.5 to 3 mg/dL	0	2 (1)
Platelet count 25K to <50K/mm ³	1 (<1)	1 (<1)

Sofosbuvir-Velpatasvir in HCV Genotype 3 ASTRAL-3: Conclusions

Conclusions: “Among patients with HCV genotype [2 or] 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin.”

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.